

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER 96700/1160
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>107586892</b>
INTERNATIONAL APPLICATION NO. PCT/US2005/007365	INTERNATIONAL FILING DATE 7 March 2005 (07.03.2005)	PRIORITY DATE CLAIMED 11 March 2004 (11.03.2004)
TITLE OF INVENTION ENHANCED PRODUCTION OF FUNCTIONAL PROTEINS FROM DEFECTIVE GENES		
APPLICANT(S) FOR DO/EO/US David S. Lawrence and Biao Xi		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p>		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/586892</div>	INTERNATIONAL APPLICATION NO. PCT/US2005/007365	ATTORNEY'S DOCKET NUMBER 96700/1160
--	--	--

20. Other items or information: Copy of the International Search Report and Written Opinion.

The following fees have been submitted	CALCULATIONS	PTO USE ONLY																				
21. <input checked="" type="checkbox"/> Basic national fee (37 CFR 1.492(a))..... \$300	\$ 300.00																					
22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c))																						
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0	\$ 200.00																					
All other situations..... \$200																						
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b))																						
If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0																						
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100	\$ 100.00																					
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... \$400																						
All other situations..... \$500																						
<b>TOTAL OF 21, 22 and 23 =</b>	<b>\$ 600.00</b>																					
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">Total Sheets</th> <th style="width: 15%;">Extra Sheets</th> <th style="width: 30%;">Number of each additional 50 or fraction thereof (round up to a whole number)</th> <th style="width: 40%;">RATE</th> </tr> <tr> <td>- 100 =</td> <td>/50 =</td> <td></td> <td>x \$250</td> </tr> </table>	Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE	- 100 =	/50 =		x \$250	\$													
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE																			
- 100 =	/50 =		x \$250																			
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).	\$																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">- CLAIMS</th> <th style="width: 15%;">NUMBER FILED</th> <th style="width: 15%;">NUMBER EXTRA</th> <th style="width: 15%;">RATE</th> <th style="width: 40%;">\$</th> </tr> <tr> <td>Total claims</td> <td>- 20 =</td> <td></td> <td>x \$ 50</td> <td>\$ 900.00</td> </tr> <tr> <td>Independent claims</td> <td>- 3 =</td> <td></td> <td>x \$200</td> <td>\$ 0</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$360</td> </tr> </table>	- CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	- 20 =		x \$ 50	\$ 900.00	Independent claims	- 3 =		x \$200	\$ 0	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	\$	
- CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																		
Total claims	- 20 =		x \$ 50	\$ 900.00																		
Independent claims	- 3 =		x \$200	\$ 0																		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360																		
<b>TOTAL OF ABOVE CALCULATIONS =</b>	<b>\$ 1500.00</b>																					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.																						
<b>SUBTOTAL =</b>	<b>\$ 750.00</b>																					
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).	\$																					
<b>TOTAL NATIONAL FEE =</b>	<b>\$ 750.00</b>																					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	\$																					
<b>TOTAL FEES ENCLOSED =</b>	<b>\$ 750.00</b>																					
	Amount to be refunded:	\$																				
	Amount to be charged	\$																				


AP20 Rec'd PST/PTO 20 JUL 2006

- a. ☒ A check in the amount of \$ 750.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-1785. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

## SEND ALL CORRESPONDENCE TO:

Alan D. Miller  
Amster, Rothstein & Ebenstein LLP  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000



SIGNATURE

Alan D. Miller

NAME

42,889

REGISTRATION NUMBER

10/586892

**AMSTER  
ROTHSTEIN  
& EBENSTEIN LLP***Intellectual Property Law*90 Park Avenue  
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web www.arelaw.com

**Partners**Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip H. Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold  
Kenneth M. Bernstein  
Joseph M. Casino**Senior Counsel**Charles S. Miller  
Michael J. Berger  
**AP20Rec'd PCT/PTO 20 JUL 2006**  
**Associates**  
Patrick Boland\*  
John S. Economou  
Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski  
Max Vern  
Karl J. Kolbinger**Brian A. Comack**Brian A. Comack  
Elie H. Gendloff, Ph.D.  
David Mitnick  
Charles W. Rath  
David A. Boag  
Mathieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
John A. Lepore  
Norajean McCaffrey**Benjamin M. Halpern\***Matthew A. Fox  
Michael J. Kasdan  
Rebecca R. Eisenberg  
Stuart Shapley  
Howard Wizenfeld

\*Not admitted in New York

July 20, 2006

Via Express Mail


(EL 993158048 US)

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Alan D. Miller

Direct 212 336 8094

E-mail amiller@arelaw.com

"Express Mail" mailing label no. EL 993158048 US	
Date of Deposit:	July 20, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

Re: United States National Stage Filing  
of PCT Application No. PCT/US2005/007365  
Title: ENHANCED PRODUCTION OF FUNCTIONAL  
PROTEINS FROM DEFECTIVE GENES  
Applicants: David S. Lawrence and Biao Xi  
Our File: 96700/1160

Dear Sir:

Pursuant to 35 U.S.C. § 371 and 37 C.F.R. § 1.495, enclosed please find an application for patent in the names of David S. Lawrence and Biao Xi, entitled "ENHANCED PRODUCTION OF FUNCTIONAL PROTEINS FROM DEFECTIVE GENES," for entering the national stage in the United States of America, comprising the following:

1. a Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. § 371 (3 pages);
2. a copy of PCT Application No. PCT/US2005/007365 as published under PCT Publication No. WO 2005/086768 A2, including cover page (1 sheet), specification (18 pages), claims (5 pages), figures (2 pages) and sequence listing (2 pages); sequence listing on floppy disk;
3. a copy of the International Search Report and Written Opinion (10 pages);
4. a Preliminary Amendment (3 pages);

10/586892

AP20 Rec'd PCT/PTO 20 JUL 2006

Commissioner for Patents

-2-

July 20, 2006

5. an Information Disclosure Statement Forms PTO/SB/08A and PTO/SB/08B, and copies of the three non-US patent documents listed therein;
6. a check in the amount of \$750.00 to cover the filing fee; and
7. a return receipt postcard.

Please charge any outstanding amount or credit any overpayment to Deposit Account No. 01-1785. A duplicate copy of this letter is enclosed. Please also acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: New York, New York  
July 20, 2006

By: 

Alan D. Miller  
Registration No. 42,889